Effective Royalty Rates in Biopharma Alliances: What They Are & Why Use Them in Negotiations

les Nouvelles - Journal of the Licensing Executives Society, Volume LII No. 1, March 2017

18 Pages Posted: 4 Mar 2017 Last revised: 10 Mar 2018

Date Written: March 1, 2017

Abstract

Serious analysis of royalty rates in the biopharma sector requires access to unredacted, or FOIA-released, license agreements.  Upon inspection, such agreements need transformation from tiered royalties to standardized effective royalty rates (EFRs) to be most useful in ongoing negotiations.  This study reports trends in biopharma EFRs, and other financial terms, over the past three decades.

Keywords: Royalty rates, biopharma, FOIA released, tiered royalties, EFRs

Suggested Citation

Edwards, Mark, Effective Royalty Rates in Biopharma Alliances: What They Are & Why Use Them in Negotiations (March 1, 2017). les Nouvelles - Journal of the Licensing Executives Society, Volume LII No. 1, March 2017. Available at SSRN: https://ssrn.com/abstract=2904101

Mark Edwards (Contact Author)

Bioscience Addvisors ( email )

2855 Mitchell Drive
Suite 103
Walnut Creek, CA CA 94598
United States
9259541397 (Phone)

HOME PAGE: http://bioscibd.com

Register to save articles to
your library

Register

Paper statistics

Downloads
94
Abstract Views
410
rank
280,636
PlumX Metrics